Active surveillance is the preferred approach to clinical stage i testicular cancer

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3490-3493

  Nichols, Craig R ^a   Roth, Bruce ^b   Albers, Peter ^c   Einhorn, Lawrence H ^d   Foster, Richard ^d   Daneshmand, Siamak ^e   Jewett, Michael ^f   Warde, Padraig ^f   Sweeney, Christopher J ^g   Beard, Clair ^g   Powles, Tom ^h   Tyldesley, Scott ⁱ   So, Alan ⁱ   Porter, Christopher ^a   Olgac, Semra ^a   Fizazi, Karim ^j   Hayes Lattin, Brandon ^k   Grimison, Peter ^l   Toner, Guy ^m   Cathomas, Richard ⁿ   Bokemeyer, Carsten ^o   Kollmannsberger, Christian ⁱ   more..

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MALE; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TESTIS CANCER; TREATMENT DURATION; ARTICLE; CANCER STAGING; CLINICAL PRACTICE; HEALTH SURVEY; PATHOLOGY; TESTIS TUMOR; WATCHFUL WAITING; TESTICULAR NEOPLASMS;

HUMANS; MALE; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; TESTICULAR NEOPLASMS; WATCHFUL WAITING;

EID: 84891506358     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.6010     Document Type: Note

References (28)

1. Powles TB, Bhardwa J, Shamash J, et al: The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 95:1197-1200, 2005
2. Culine S, Hoppe S, Hennequin C, et al: Management of testicular neoplasms in France and compliance with national guidelines. J Clin Oncol 28:361s, 2010 (suppl; abstr 4580)
3. Arvold ND, Catalano PJ, Sweeney CJ, et al: Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 84:383-389, 2012
4. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89:1429-1439, 1997
5. Travis LB, Andersson M, Holowaty E, et al: Risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Proc Am Soc Clin Oncol 18:267, 1999 (suppl; abstr 308a)
6. Zagars GK, Ballo MT, Lee AK, et al: Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004
7. Duran I, Sturgeon JF, Jewett MA, et al: Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 25:240s, 2007 (suppl; abstr 5021)
8. Kollmannsberger C, Moore C, Chi KN, et al: Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: Diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21: 1296-1301, 2010
9. Kollmannsberger C, Tyldesley S, Moore C, et al: Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies. Ann Oncol 22:808-814, 2011
10. Tandstad T, Smaaland R, Solberg A, et al: Management of seminomatous testicular cancer: A binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol 29:719-725, 2011
11. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG)-Part I. Eur Urol 53:478-496, 2008
12. Albers P, Albrecht W, Algaba F, et al: Guidelines on testicular cancer: European Association of Urology 2011. http://www.uroweb.org/gls/pdf/10- Testicular-Cancer.pdf
13. Wood L, Kollmannsberger C, Jewett M, et al: Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4:e19-e38, 2010
14. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Testicular cancer. http://www.nccn.org/professionals/physician-gls/ pdf/testicular.pdf
15. Tandstad T, Dahl O, Cohn-Cedermark G, et al: Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol 27:2122-2128, 2009
16. Stephenson AJ, Bosl GJ, Motzer RJ, et al: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: Impact of patient selection factors on outcome. J Clin Oncol 23:2781-2788, 2005
17. Chung PW, Daugaard G, Tyldesley S, et al: Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol 28:350s, 2010 (suppl; abstr 4535)
18. Warde P, Specht L, Horwich A, et al: Prognostic factors for relapse in stage I seminoma managed by surveillance: A pooled analysis. J Clin Oncol 20:4448-4452, 2002
19. Albers P, Siener R, Krege S, et al: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966-2972, 2008
20. Horwich A, Fossa SD, Stenning SP, et al: Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. J Clin Oncol 28:351s, 2010 (suppl; abstr 4538)
21. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatmentspecific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
22. Oliver RT, Mead GM, Rustin GJ, et al: Randomized trial of carboplatin versus radiotherapy for stage I seminoma: Mature results on relapse andcontralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29:957-962, 2011
23. Aparicio J, Germà JR, García del Muro X, et al: Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717-8723, 2005
24. Groll RJ, Warde P, Jewett MA: A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 64:182-197, 2007
25. Warde P, Gospodarowicz MK, Panzarella T, et al: Stage I testicular seminoma: Results of adjuvant irradiation and surveillance. J Clin Oncol 13:2255-2262, 1995
26. Rustin GJ, Mead GM, Stenning SP, et al: Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Res Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25:1310-1315, 2007
27. Cathomas R, Helbling D, Stenner F, et al: Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: A joint effort. Swiss Med Wkly 140:356-369, 2010
28. Thibault C, Loriot Y, Barrios Gonzales D, et al: Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy. J Clin Oncol 30, 2012 (suppl 5; abstr 323)